| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiotensin I | 37 | 2020 | 262 | 4.580 |
Why?
|
| Peptide Fragments | 38 | 2020 | 422 | 4.520 |
Why?
|
| Peptidyl-Dipeptidase A | 22 | 2017 | 142 | 1.980 |
Why?
|
| Angiotensin II | 29 | 2015 | 279 | 1.610 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 546 | 1.400 |
Why?
|
| Renin-Angiotensin System | 17 | 2012 | 182 | 1.330 |
Why?
|
| Rats | 40 | 2020 | 1604 | 1.000 |
Why?
|
| Animals | 54 | 2020 | 7299 | 0.930 |
Why?
|
| Antihypertensive Agents | 6 | 2015 | 342 | 0.920 |
Why?
|
| RNA, Messenger | 28 | 2015 | 514 | 0.890 |
Why?
|
| Baroreflex | 8 | 2015 | 84 | 0.830 |
Why?
|
| Renin | 14 | 2012 | 112 | 0.800 |
Why?
|
| Solitary Nucleus | 7 | 2015 | 34 | 0.750 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2020 | 747 | 0.730 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2010 | 134 | 0.720 |
Why?
|
| Receptor, Angiotensin, Type 1 | 12 | 2013 | 75 | 0.720 |
Why?
|
| Doxorubicin | 1 | 2020 | 55 | 0.720 |
Why?
|
| Heart Rate | 9 | 2020 | 315 | 0.710 |
Why?
|
| Heart Diseases | 2 | 2020 | 99 | 0.710 |
Why?
|
| Carboxypeptidases | 6 | 2005 | 20 | 0.700 |
Why?
|
| Antioxidants | 1 | 2020 | 114 | 0.690 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 301 | 0.680 |
Why?
|
| Oxidative Stress | 6 | 2012 | 223 | 0.680 |
Why?
|
| Imidazoles | 9 | 2011 | 104 | 0.660 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 384 | 0.640 |
Why?
|
| Hypertension | 11 | 2015 | 910 | 0.580 |
Why?
|
| Myocytes, Cardiac | 2 | 2008 | 87 | 0.580 |
Why?
|
| MAP Kinase Signaling System | 5 | 2015 | 57 | 0.570 |
Why?
|
| Gene Expression Regulation | 9 | 2015 | 481 | 0.520 |
Why?
|
| Receptor, Angiotensin, Type 2 | 6 | 2013 | 23 | 0.510 |
Why?
|
| Blood Pressure | 19 | 2015 | 806 | 0.490 |
Why?
|
| Uterus | 6 | 2015 | 73 | 0.480 |
Why?
|
| Peptide Hormones | 1 | 2014 | 11 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2009 | 90 | 0.480 |
Why?
|
| Receptors, G-Protein-Coupled | 8 | 2011 | 89 | 0.460 |
Why?
|
| MEDLINE | 2 | 2002 | 3 | 0.430 |
Why?
|
| Osteoclasts | 1 | 2012 | 22 | 0.430 |
Why?
|
| Fibrosis | 8 | 2016 | 103 | 0.430 |
Why?
|
| Cell Proliferation | 5 | 2014 | 573 | 0.420 |
Why?
|
| Dual Specificity Phosphatase 1 | 7 | 2015 | 29 | 0.420 |
Why?
|
| Fibroblasts | 2 | 2012 | 103 | 0.420 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 666 | 0.420 |
Why?
|
| Leucine | 2 | 2010 | 24 | 0.420 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 11 | 2015 | 68 | 0.410 |
Why?
|
| Pre-Eclampsia | 4 | 2015 | 53 | 0.400 |
Why?
|
| Angiotensins | 1 | 2011 | 49 | 0.390 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 9 | 0.390 |
Why?
|
| Astrocytes | 2 | 2013 | 49 | 0.380 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 441 | 0.380 |
Why?
|
| Estradiol | 3 | 2011 | 118 | 0.380 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 28 | 0.380 |
Why?
|
| Kidney | 8 | 2012 | 486 | 0.370 |
Why?
|
| Mice | 13 | 2016 | 2370 | 0.360 |
Why?
|
| Ovariectomy | 7 | 2010 | 147 | 0.360 |
Why?
|
| Losartan | 8 | 2009 | 69 | 0.350 |
Why?
|
| Cells, Cultured | 9 | 2013 | 799 | 0.350 |
Why?
|
| Heart Ventricles | 2 | 2010 | 107 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2008 | 4 | 0.340 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2008 | 71 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 37 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2015 | 44 | 0.330 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 50 | 0.320 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 74 | 0.320 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 50 | 0.320 |
Why?
|
| Cell Division | 2 | 2005 | 97 | 0.310 |
Why?
|
| Angiotensinogen | 7 | 2012 | 73 | 0.310 |
Why?
|
| Apolipoproteins E | 1 | 2008 | 97 | 0.310 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2012 | 29 | 0.310 |
Why?
|
| Mice, Nude | 5 | 2012 | 276 | 0.310 |
Why?
|
| Cell Line, Tumor | 6 | 2012 | 681 | 0.310 |
Why?
|
| Male | 30 | 2020 | 17815 | 0.300 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2012 | 113 | 0.290 |
Why?
|
| Rats, Inbred Lew | 12 | 2015 | 116 | 0.290 |
Why?
|
| Tetrazoles | 8 | 2011 | 71 | 0.280 |
Why?
|
| Myocardium | 4 | 2020 | 170 | 0.270 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2005 | 7 | 0.270 |
Why?
|
| Ventricular Remodeling | 4 | 2011 | 52 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 69 | 0.270 |
Why?
|
| Aging | 6 | 2015 | 881 | 0.260 |
Why?
|
| Endocannabinoids | 2 | 2015 | 34 | 0.260 |
Why?
|
| Female | 22 | 2020 | 18173 | 0.260 |
Why?
|
| Medulla Oblongata | 3 | 2012 | 53 | 0.250 |
Why?
|
| Evidence-Based Medicine | 2 | 2002 | 207 | 0.240 |
Why?
|
| Neprilysin | 6 | 2012 | 32 | 0.240 |
Why?
|
| Pregnancy | 7 | 2015 | 815 | 0.230 |
Why?
|
| Humans | 20 | 2017 | 29123 | 0.230 |
Why?
|
| Placenta | 4 | 2013 | 63 | 0.230 |
Why?
|
| Receptors, Angiotensin | 4 | 2013 | 77 | 0.230 |
Why?
|
| Gene Expression Regulation, Enzymologic | 6 | 2015 | 83 | 0.230 |
Why?
|
| Bone Marrow Cells | 3 | 2012 | 114 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2012 | 37 | 0.220 |
Why?
|
| Chorionic Villi | 2 | 2015 | 7 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 103 | 0.210 |
Why?
|
| Information Storage and Retrieval | 1 | 2002 | 24 | 0.210 |
Why?
|
| Hypertension, Renal | 3 | 2006 | 29 | 0.210 |
Why?
|
| Malondialdehyde | 2 | 2020 | 9 | 0.200 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 159 | 0.200 |
Why?
|
| Cardiomegaly | 2 | 2011 | 30 | 0.190 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 494 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 81 | 0.190 |
Why?
|
| Pancreas | 1 | 2001 | 79 | 0.190 |
Why?
|
| Catalase | 1 | 2020 | 16 | 0.190 |
Why?
|
| Superoxide Dismutase | 1 | 2020 | 47 | 0.180 |
Why?
|
| Brain | 4 | 2012 | 930 | 0.180 |
Why?
|
| Mitral Valve | 1 | 2020 | 28 | 0.180 |
Why?
|
| Phosphorylation | 4 | 2015 | 225 | 0.170 |
Why?
|
| Animals, Newborn | 3 | 2012 | 111 | 0.170 |
Why?
|
| Flavonoids | 2 | 2008 | 18 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 82 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 77 | 0.160 |
Why?
|
| Disease Models, Animal | 9 | 2016 | 980 | 0.160 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2017 | 5 | 0.160 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 40 | 0.150 |
Why?
|
| Lisinopril | 3 | 2006 | 28 | 0.150 |
Why?
|
| Up-Regulation | 4 | 2015 | 183 | 0.150 |
Why?
|
| Estrogens | 2 | 2010 | 162 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2015 | 143 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 4 | 2015 | 62 | 0.140 |
Why?
|
| Proteinuria | 3 | 2011 | 57 | 0.140 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 4 | 0.140 |
Why?
|
| Spasm | 1 | 2016 | 5 | 0.140 |
Why?
|
| Autonomic Nervous System | 2 | 2012 | 42 | 0.130 |
Why?
|
| Neoplasms | 2 | 2014 | 611 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2010 | 281 | 0.130 |
Why?
|
| Amidohydrolases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2015 | 5 | 0.130 |
Why?
|
| Receptors, Cannabinoid | 1 | 2015 | 26 | 0.130 |
Why?
|
| Leptin | 3 | 2011 | 66 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 248 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 100 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2012 | 17 | 0.130 |
Why?
|
| Embryo Implantation | 1 | 2015 | 35 | 0.130 |
Why?
|
| Endothelin-1 | 3 | 2012 | 17 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 66 | 0.120 |
Why?
|
| Rats, Transgenic | 5 | 2012 | 52 | 0.120 |
Why?
|
| Stromal Cells | 2 | 2004 | 70 | 0.120 |
Why?
|
| Animals, Genetically Modified | 7 | 2008 | 67 | 0.120 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 5 | 0.120 |
Why?
|
| Pyridines | 4 | 2009 | 78 | 0.120 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 280 | 0.120 |
Why?
|
| Heart | 2 | 2012 | 162 | 0.110 |
Why?
|
| Cyclopentanes | 2 | 2011 | 17 | 0.110 |
Why?
|
| Quinolines | 2 | 2011 | 27 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sodium Chloride | 1 | 2012 | 24 | 0.110 |
Why?
|
| Ethanolamines | 1 | 2012 | 16 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.110 |
Why?
|
| Ornithine | 1 | 2012 | 4 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2012 | 71 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2012 | 666 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 298 | 0.100 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2011 | 5 | 0.100 |
Why?
|
| Phenylephrine | 2 | 2008 | 27 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 199 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 104 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 46 | 0.100 |
Why?
|
| Fibronectins | 1 | 2010 | 34 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 158 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2012 | 30 | 0.090 |
Why?
|
| Neuroglia | 2 | 2006 | 29 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 34 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2006 | 50 | 0.090 |
Why?
|
| Valine | 2 | 2006 | 17 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2008 | 425 | 0.090 |
Why?
|
| Butadienes | 1 | 2008 | 7 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 10 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2012 | 239 | 0.080 |
Why?
|
| Vanadates | 1 | 2008 | 2 | 0.080 |
Why?
|
| Okadaic Acid | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 136 | 0.080 |
Why?
|
| Nitriles | 1 | 2008 | 22 | 0.080 |
Why?
|
| Aorta, Thoracic | 2 | 2009 | 72 | 0.080 |
Why?
|
| Membranes | 1 | 2008 | 11 | 0.080 |
Why?
|
| Radioimmunoassay | 1 | 2008 | 21 | 0.080 |
Why?
|
| Pregnancy, Animal | 1 | 2007 | 19 | 0.080 |
Why?
|
| Kinetics | 2 | 2006 | 205 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 9 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 36 | 0.070 |
Why?
|
| Reference Values | 3 | 2016 | 224 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2006 | 92 | 0.070 |
Why?
|
| Lung | 1 | 2008 | 233 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 35 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 34 | 0.070 |
Why?
|
| Cerebellum | 1 | 2005 | 29 | 0.070 |
Why?
|
| Aged | 4 | 2012 | 9492 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 26 | 0.070 |
Why?
|
| Rats, Inbred SHR | 3 | 2012 | 42 | 0.070 |
Why?
|
| Glycerides | 2 | 2015 | 13 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 519 | 0.070 |
Why?
|
| Arachidonic Acids | 2 | 2015 | 23 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 142 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 35 | 0.060 |
Why?
|
| Time Factors | 4 | 2012 | 2001 | 0.060 |
Why?
|
| Nitric Oxide | 3 | 2012 | 116 | 0.060 |
Why?
|
| Gene Expression | 3 | 2013 | 332 | 0.060 |
Why?
|
| Culture Media | 1 | 2004 | 39 | 0.060 |
Why?
|
| DNA Replication | 1 | 2004 | 23 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 172 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 3 | 0.060 |
Why?
|
| Carotid Arteries | 2 | 2005 | 97 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 95 | 0.060 |
Why?
|
| Dinoprost | 1 | 2003 | 10 | 0.060 |
Why?
|
| Microinjections | 2 | 2015 | 33 | 0.060 |
Why?
|
| Random Allocation | 2 | 2016 | 213 | 0.050 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2002 | 1 | 0.050 |
Why?
|
| Subject Headings | 1 | 2002 | 1 | 0.050 |
Why?
|
| Animals, Congenic | 3 | 2007 | 14 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 454 | 0.050 |
Why?
|
| Decidua | 2 | 2015 | 17 | 0.050 |
Why?
|
| Research | 1 | 2002 | 72 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 532 | 0.050 |
Why?
|
| Internet | 1 | 2002 | 156 | 0.050 |
Why?
|
| Middle Aged | 2 | 2012 | 10834 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 413 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 464 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2012 | 37 | 0.040 |
Why?
|
| Nitrates | 2 | 2012 | 25 | 0.040 |
Why?
|
| Inflammation | 2 | 2013 | 507 | 0.040 |
Why?
|
| Injections | 2 | 2012 | 61 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2000 | 109 | 0.040 |
Why?
|
| Protein Stability | 1 | 2017 | 26 | 0.040 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.030 |
Why?
|
| Benzimidazoles | 2 | 2006 | 33 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 43 | 0.030 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2015 | 5 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2015 | 22 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 17 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 57 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 89 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 56 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 40 | 0.030 |
Why?
|
| Body Weight | 2 | 2009 | 290 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 68 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 72 | 0.030 |
Why?
|
| Pseudopregnancy | 1 | 2015 | 4 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 2015 | 5 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2015 | 7 | 0.030 |
Why?
|
| Arterioles | 1 | 2015 | 12 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 7 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2015 | 11 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2015 | 65 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 99 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2015 | 51 | 0.030 |
Why?
|
| Adult | 3 | 2015 | 8426 | 0.030 |
Why?
|
| Piperidines | 1 | 2015 | 125 | 0.030 |
Why?
|
| United States | 1 | 2002 | 3632 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 58 | 0.030 |
Why?
|
| Myometrium | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 370 | 0.030 |
Why?
|
| Gestational Age | 1 | 2013 | 96 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Ion Channels | 1 | 2012 | 24 | 0.030 |
Why?
|
| Biopterin | 1 | 2012 | 3 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 10 | 0.030 |
Why?
|
| Nitrites | 1 | 2012 | 20 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 69 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 32 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 67 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2011 | 80 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 1108 | 0.030 |
Why?
|
| Mesenteric Arteries | 1 | 2011 | 18 | 0.030 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2011 | 5 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 2011 | 24 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2011 | 39 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 320 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 125 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 87 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 160 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 174 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 217 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 274 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 204 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.020 |
Why?
|
| Bradycardia | 1 | 2009 | 15 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2009 | 4 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2009 | 29 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 21 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 33 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 150 | 0.020 |
Why?
|
| Alanine | 1 | 2009 | 27 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2009 | 73 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 118 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 172 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 2402 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 196 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 106 | 0.020 |
Why?
|
| Biguanides | 1 | 2008 | 3 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 631 | 0.020 |
Why?
|
| Yolk Sac | 1 | 2007 | 2 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 179 | 0.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2007 | 10 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 641 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 26 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 373 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 45 | 0.020 |
Why?
|
| Amnion | 1 | 2007 | 36 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 72 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 80 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2006 | 12 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 2006 | 3 | 0.020 |
Why?
|
| Aldosterone | 1 | 2006 | 28 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2007 | 138 | 0.020 |
Why?
|
| Kidney Cortex | 1 | 2006 | 25 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 2006 | 29 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2006 | 63 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 23 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 33 | 0.020 |
Why?
|
| Heterozygote | 1 | 2006 | 52 | 0.020 |
Why?
|
| Podocytes | 1 | 2006 | 20 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 232 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 30 | 0.020 |
Why?
|
| Tail | 1 | 2005 | 6 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 162 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2007 | 256 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2006 | 167 | 0.020 |
Why?
|
| Atenolol | 1 | 2005 | 6 | 0.020 |
Why?
|
| Hydralazine | 1 | 2005 | 8 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 1688 | 0.020 |
Why?
|
| Albuminuria | 1 | 2006 | 177 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 59 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2004 | 5 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 54 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2004 | 67 | 0.020 |
Why?
|
| Polyuria | 1 | 2004 | 2 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 31 | 0.020 |
Why?
|
| Diuresis | 1 | 2004 | 9 | 0.020 |
Why?
|
| Ligation | 1 | 2004 | 55 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2004 | 77 | 0.020 |
Why?
|
| Hypotension | 1 | 2004 | 47 | 0.010 |
Why?
|
| F2-Isoprostanes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 346 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2004 | 389 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2004 | 147 | 0.010 |
Why?
|
| Chemoreceptor Cells | 1 | 2002 | 3 | 0.010 |
Why?
|
| Substance P | 1 | 2002 | 22 | 0.010 |
Why?
|
| Vagus Nerve | 1 | 2002 | 29 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 3719 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 148 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 572 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 35 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 2000 | 29 | 0.010 |
Why?
|
| Macrophages | 1 | 2000 | 188 | 0.010 |
Why?
|